title: Comparison of the effects of metoprolol or carvedilol on serum gamma-glutamyltransferase and uric acid levels among patients with acute coronary syndrome without ST segment elevation.
abstract: OBJECTIVE
  Serum gamma-glutamyltransferase (GGT) and uric acid levels measured in patients with acute coronary syndrome without ST segment elevation (NSTEMI) are important in diagnosis and in predicting the prognosis of the disease. There is a limited number of clinical studies investigating the effects of beta-blockers on GGT and uric acid levels in these patients. In our study, we aimed to investigate the effects of beta-blocker therapy on GGT and uric acid levels.
  
  
  METHODS
  We conducted a randomized, prospective clinical study. Hundred patients with NSTEMI were included in this study, and they were divided into two groups. Fifty patients were administered metoprolol succinate treatment (1 x 50 mg), whereas the remaining 50 patients were administered carvedilol treatment (2 x 12.5 mg). Thereafter, all of the patients underwent coronary angiography. Blood samples were taken at the time of admission, at the 1st month, and 3rd month to detect GGT and uric acid levels.
  
  
  RESULTS
  There was no statistically significant difference among the metoprolol or carvedilol groups in terms of the GGT levels measured at the baseline, 1st month, and 3rd month (p=0.904 and p=0.573, respectively). In addition, there was no statistically significant difference among the metoprolol or carvedilol groups in terms of uric acid levels measured at the baseline, 1st month, and 3rd month (p=0.601 and p=0.601, respectively).
  
  
  CONCLUSIONS
  We found that GGT and uric acid levels did not show any change compared to the baseline values, with metoprolol and carvedilol treatment initiated in the early period in patients with NSTEMI.
authors.affiliation: Department of Cardiology, Faculty of Medicine, Atatürk University; Erzurum-Turkey. lutfuaskin23@gmail.com.
authors.forename: Lütfü
authors.initials: L
authors.lastname: Aşkın
authors.forename: Şule
authors.initials: Ş
authors.lastname: Karakelleoğlu
authors.forename: Hüsnü
authors.initials: H
authors.lastname: Değirmenci
authors.forename: Selami
authors.initials: S
authors.lastname: Demirelli
authors.forename: Ziya
authors.initials: Z
authors.lastname: Şimşek
authors.forename: Muhammed Hakan
authors.initials: MH
authors.lastname: Taş
authors.forename: Selim
authors.initials: S
authors.lastname: Topçu
authors.forename: Zakir
authors.initials: Z
authors.lastname: Lazoğlu
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000368:Aged; D002227:Carbazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000077261:Carvedilol; D005260:Female; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011412:Propanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D014527:Uric Acid; D005723:gamma-Glutamyltransferase; D008790:Metoprolol